KinCSM: Using graph‐based signatures to predict small molecule CDK2 inhibitors. (26th October 2022)

• Record Type: Journal Article
• Authors: Zhou, Yunzhuo; Al‐Jarf, Raghad; Alavi, Azadeh; Nguyen, Thanh Binh; Rodrigues, Carlos H. M.; Pires, Douglas E. V.; Ascher, David B.
• Is Part Of: Protein science. Volume 31:Number 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-10-26
• Subjects: bioactivity prediction -- CDK2 inhibitors -- graph‐based signatures -- kinase inhibitors -- machine learning -- small molecules; Proteins -- Periodicals; 572.6
• DOI: 10.1002/pro.4453
• Languages: English
• ISSNs: 0961-8368

Abstract

Abstract: Protein phosphorylation acts as an essential on/off switch in many cellular signaling pathways. This has led to ongoing interest in targeting kinases for therapeutic intervention. Computer‐aided drug discovery has been proven a useful and cost‐effective approach for facilitating prioritization and enrichment of screening libraries, but limited effort has been devoted providing insights on what makes a potent kinase inhibitor. To fill this gap, here we developed kinCSM, an integrative computational tool capable of accurately identifying potent cyclin‐dependent kinase 2 (CDK2) inhibitors, quantitatively predicting CDK2 ligand–kinase inhibition constants (pKi ) and classifying different types of inhibitors based on their favorable binding modes. kinCSM predictive models were built using supervised learning and leveraged the concept of graph‐based signatures to capture both physicochemical properties and geometry properties of small molecules. CDK2 inhibitors were accurately identified with Matthew's Correlation Coefficients (MCC) of up to 0.74, and inhibition constants predicted with Pearson's correlation of up to 0.76, both with consistent performances of 0.66 and 0.68 on a nonredundant blind test, respectively. kinCSM was also able to identify the potential type of inhibition for a given molecule, achieving MCC of up to 0.80 on cross‐validation and 0.73 on the blind test. Analyzing the molecular composition of revealed enriched chemical fragments in CDK2 inhibitors and different types of inhibitors, which provides insights into the molecular mechanisms behind ligand–kinase interactions. kinCSM will be an invaluable tool to guide future kinase drug discovery. To aid the fast and accurate screening of CDK2 inhibitors, kinCSM is freely available at https://biosig.lab.uq.edu.au/kin_csm/ .